Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-10-26
DOI
10.1038/s41379-018-0160-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Indoleamine-2,3-Dioxygenase in Non–Small Cell Lung Cancer
- (2018) Ashley Volaric et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells
- (2018) Ailin Li et al. CANCER LETTERS
- PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma
- (2018) Matthew W. Rosenbaum et al. ENDOCRINE PATHOLOGY
- Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma
- (2018) Yuka Kozuma et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases
- (2017) Hironori Uruga et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma
- (2017) Chun-Yu Lin et al. PLoS One
- Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society
- (2016) Lynette M. Sholl et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
- (2016) Kurt A. Schalper et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment
- (2016) Tiffany G. Huynh et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
- (2016) Masaki Shimoji et al. LUNG CANCER
- Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
- (2016) Jamaal A Rehman et al. MODERN PATHOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
- (2016) Mari Mino-Kenudson et al. Cancer Biology & Medicine
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
- (2015) M. Ilie et al. ANNALS OF ONCOLOGY
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
- (2015) L. Zhai et al. CLINICAL CANCER RESEARCH
- PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
- (2015) Wendy A. Cooper et al. LUNG CANCER
- Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
- (2015) Jaemoon Koh et al. MODERN PATHOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the indoleamine 2,3-dioxygenase pathway in cancer
- (2015) Yong Wha Moon et al. Journal for ImmunoTherapy of Cancer
- PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
- (2015) Lars Henning Schmidt et al. PLoS One
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
- (2014) K. Azuma et al. ANNALS OF ONCOLOGY
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
- (2014) Yang Zhang et al. OncoTargets and Therapy
- Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
- (2014) I. Theate et al. Cancer Immunology Research
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
- (2013) T. Z. Iversen et al. CLINICAL CANCER RESEARCH
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: Unusually high frequency of down-regulation in breast cancer tissues
- (2012) Toshihiko Torigoe et al. PATHOLOGY INTERNATIONAL
- IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
- (2012) Courtney Smith et al. Cancer Discovery
- Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer
- (2011) L Ferdinande et al. BRITISH JOURNAL OF CANCER
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
- (2010) Dora Dias-Santagata et al. EMBO Molecular Medicine
- Prognostic significance of grading in lung adenocarcinoma
- (2009) Justine A. Barletta et al. CANCER
- The New Lung Cancer Staging System
- (2009) Frank C. Detterbeck et al. CHEST
- Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas
- (2009) Sanja Dacic et al. MODERN PATHOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started